UA75881C2 - A humanized antibody being associated with beta-amyloid peptide ((a?- polynucleic acid coding it, a pharmaceutical composition containing it, and use of said humanized antibody for making medicinal agent for prophylaxis and treatment of states associated with formation of beta-amyloid plaques - Google Patents

A humanized antibody being associated with beta-amyloid peptide ((a?- polynucleic acid coding it, a pharmaceutical composition containing it, and use of said humanized antibody for making medicinal agent for prophylaxis and treatment of states associated with formation of beta-amyloid plaques Download PDF

Info

Publication number: UA75881C2
Authority: UA; Ukraine
Prior art keywords: bek; haa; sequence; antibody; humanized antibody
Prior art date: 2000-02-24

Application number

UA2002086888A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Univ Washington

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-24

Filing date

2001-02-26

Publication date

2006-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27391859&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA75881(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-02-26 Application filed by Univ Washington, Lilly Co Eli filed Critical Univ Washington

2006-06-15 Publication of UA75881C2 publication Critical patent/UA75881C2/uk

Links

238000011282 treatment Methods 0.000 title claims abstract description 28
108091033319 polynucleotide Proteins 0.000 title claims abstract description 21
102000040430 polynucleotide Human genes 0.000 title claims abstract description 21
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
208000037259 Amyloid Plaque Diseases 0.000 title abstract description 18
108010090849 Amyloid beta-Peptides Proteins 0.000 title abstract description 10
102000013455 Amyloid beta-Peptides Human genes 0.000 title abstract description 10
230000015572 biosynthetic process Effects 0.000 title abstract description 9
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title abstract description 6
238000011321 prophylaxis Methods 0.000 title abstract description 3
239000003795 chemical substances by application Substances 0.000 title abstract 2
208000024827 Alzheimer disease Diseases 0.000 claims abstract description 21
208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims abstract description 11
230000002265 prevention Effects 0.000 claims abstract description 8
241000282414 Homo sapiens Species 0.000 claims description 84
239000012634 fragment Substances 0.000 claims description 67
108060003951 Immunoglobulin Proteins 0.000 claims description 34
102000018358 immunoglobulin Human genes 0.000 claims description 34
210000004027 cell Anatomy 0.000 claims description 31
230000014509 gene expression Effects 0.000 claims description 19
201000010374 Down Syndrome Diseases 0.000 claims description 13
208000010877 cognitive disease Diseases 0.000 claims description 10
208000028698 Cognitive impairment Diseases 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 9
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
206010044688 Trisomy 21 Diseases 0.000 claims description 4
201000000050 myeloid neoplasm Diseases 0.000 claims description 4
229940126601 medicinal product Drugs 0.000 claims description 3
210000001672 ovary Anatomy 0.000 claims description 3
241000699673 Mesocricetus auratus Species 0.000 claims description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
210000003292 kidney cell Anatomy 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
230000002035 prolonged effect Effects 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 4
101000703761 Homo sapiens Leucine-rich repeat protein SHOC-2 Proteins 0.000 claims 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
102100031956 Leucine-rich repeat protein SHOC-2 Human genes 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 19
201000010099 disease Diseases 0.000 abstract description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
230000006866 deterioration Effects 0.000 abstract description 2
208000011580 syndromic disease Diseases 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 description 107
241000699670 Mus sp. Species 0.000 description 58
150000001413 amino acids Chemical class 0.000 description 57
210000001175 cerebrospinal fluid Anatomy 0.000 description 49
210000002381 plasma Anatomy 0.000 description 47
235000001014 amino acid Nutrition 0.000 description 46
238000000034 method Methods 0.000 description 43
210000004556 brain Anatomy 0.000 description 29
241001529936 Murinae Species 0.000 description 28
238000002347 injection Methods 0.000 description 24
239000007924 injection Substances 0.000 description 24
230000027455 binding Effects 0.000 description 23
241001465754 Metazoa Species 0.000 description 21
241000699666 Mus <mouse, genus> Species 0.000 description 21
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 21
239000002953 phosphate buffered saline Substances 0.000 description 19
210000003169 central nervous system Anatomy 0.000 description 18
239000000203 mixture Substances 0.000 description 18
210000004369 blood Anatomy 0.000 description 14
239000008280 blood Substances 0.000 description 14
239000002157 polynucleotide Substances 0.000 description 14
208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 13
230000009919 sequestration Effects 0.000 description 13
238000001262 western blot Methods 0.000 description 13
239000000243 solution Substances 0.000 description 12
238000011830 transgenic mouse model Methods 0.000 description 12
238000001514 detection method Methods 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
229940072221 immunoglobulins Drugs 0.000 description 11
102000004196 processed proteins & peptides Human genes 0.000 description 11
210000003710 cerebral cortex Anatomy 0.000 description 10
239000000499 gel Substances 0.000 description 10
101150037123 APOE gene Proteins 0.000 description 9
101100216294 Danio rerio apoeb gene Proteins 0.000 description 9
241000282412 Homo Species 0.000 description 9
241000699660 Mus musculus Species 0.000 description 9
230000008021 deposition Effects 0.000 description 9
210000004602 germ cell Anatomy 0.000 description 9
239000012528 membrane Substances 0.000 description 9
239000013598 vector Substances 0.000 description 9
238000002965 ELISA Methods 0.000 description 8
101100018424 Mus musculus Ids gene Proteins 0.000 description 8
108091028043 Nucleic acid sequence Proteins 0.000 description 8
230000008499 blood brain barrier function Effects 0.000 description 8
210000001218 blood-brain barrier Anatomy 0.000 description 8
239000000872 buffer Substances 0.000 description 8
235000018102 proteins Nutrition 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
239000011534 wash buffer Substances 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 7
230000001149 cognitive effect Effects 0.000 description 7
239000002299 complementary DNA Substances 0.000 description 7
238000011161 development Methods 0.000 description 7
210000004379 membrane Anatomy 0.000 description 7
238000005406 washing Methods 0.000 description 7
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 6
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
230000008859 change Effects 0.000 description 6
230000003053 immunization Effects 0.000 description 6
238000002649 immunization Methods 0.000 description 6
230000005847 immunogenicity Effects 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
239000002609 medium Substances 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
241000894007 species Species 0.000 description 6
238000010186 staining Methods 0.000 description 6
231100000331 toxic Toxicity 0.000 description 6
230000002588 toxic effect Effects 0.000 description 6
230000003442 weekly effect Effects 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
229940098773 bovine serum albumin Drugs 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000013604 expression vector Substances 0.000 description 5
230000006870 function Effects 0.000 description 5
238000001502 gel electrophoresis Methods 0.000 description 5
238000011534 incubation Methods 0.000 description 5
238000010253 intravenous injection Methods 0.000 description 5
230000002441 reversible effect Effects 0.000 description 5
239000007790 solid phase Substances 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
238000012546 transfer Methods 0.000 description 5
230000009261 transgenic effect Effects 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
108020004705 Codon Proteins 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
108090001030 Lipoproteins Proteins 0.000 description 4
102000004895 Lipoproteins Human genes 0.000 description 4
239000000020 Nitrocellulose Substances 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
239000000427 antigen Substances 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
230000006399 behavior Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
239000000539 dimer Substances 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000001378 electrochemiluminescence detection Methods 0.000 description 4
210000004408 hybridoma Anatomy 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
230000000977 initiatory effect Effects 0.000 description 4
230000014759 maintenance of location Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
229920001220 nitrocellulos Polymers 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
230000007505 plaque formation Effects 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
238000003752 polymerase chain reaction Methods 0.000 description 4
230000000644 propagated effect Effects 0.000 description 4
238000003127 radioimmunoassay Methods 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
240000003291 Armoracia rusticana Species 0.000 description 3
235000011330 Armoracia rusticana Nutrition 0.000 description 3
241000195940 Bryophyta Species 0.000 description 3
241000283707 Capra Species 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 3
108010001336 Horseradish Peroxidase Proteins 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
206010057249 Phagocytosis Diseases 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
101800004937 Protein C Proteins 0.000 description 3
241000700159 Rattus Species 0.000 description 3
101800001700 Saposin-D Proteins 0.000 description 3
102400000827 Saposin-D Human genes 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
238000007792 addition Methods 0.000 description 3
238000001042 affinity chromatography Methods 0.000 description 3
108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 3
239000013060 biological fluid Substances 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000003931 cognitive performance Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000012228 culture supernatant Substances 0.000 description 3
230000006735 deficit Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
230000035876 healing Effects 0.000 description 3
210000001320 hippocampus Anatomy 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000007170 pathology Effects 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
230000008782 phagocytosis Effects 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
229960000856 protein c Drugs 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
206010059245 Angiopathy Diseases 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
241000282994 Cervidae Species 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
241001026509 Kata Species 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241001494479 Pecora Species 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
239000006096 absorbing agent Substances 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000004087 circulation Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
239000012636 effector Substances 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000011544 gradient gel Substances 0.000 description 2
102000046783 human APP Human genes 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
244000005700 microbiome Species 0.000 description 2
210000000274 microglia Anatomy 0.000 description 2
239000000178 monomer Substances 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
235000006408 oxalic acid Nutrition 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000035515 penetration Effects 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
210000000578 peripheral nerve Anatomy 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
-1 polypropylene Polymers 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
239000002516 radical scavenger Substances 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000009738 saturating Methods 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
238000003153 stable transfection Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
238000012384 transportation and delivery Methods 0.000 description 2
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
102000001049 Amyloid Human genes 0.000 description 1
108010094108 Amyloid Proteins 0.000 description 1
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
244000099147 Ananas comosus Species 0.000 description 1
235000007119 Ananas comosus Nutrition 0.000 description 1
102100029470 Apolipoprotein E Human genes 0.000 description 1
101710095339 Apolipoprotein E Proteins 0.000 description 1
102000013918 Apolipoproteins E Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
241001186557 Arrup Species 0.000 description 1
241000501754 Astronotus ocellatus Species 0.000 description 1
241000786798 Atya Species 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
OWNRRUFOJXFKCU-UHFFFAOYSA-N Bromadiolone Chemical compound C=1C=C(C=2C=CC(Br)=CC=2)C=CC=1C(O)CC(C=1C(OC2=CC=CC=C2C=1O)=O)C1=CC=CC=C1 OWNRRUFOJXFKCU-UHFFFAOYSA-N 0.000 description 1
101100492787 Caenorhabditis elegans mai-1 gene Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010008111 Cerebral haemorrhage Diseases 0.000 description 1
241000511343 Chondrostoma nasus Species 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
235000017788 Cydonia oblonga Nutrition 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
108700007698 Genetic Terminator Regions Proteins 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
101000628693 Homo sapiens Serine/threonine-protein kinase 25 Proteins 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
241000764773 Inna Species 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108091036060 Linker DNA Proteins 0.000 description 1
101150049547 Lyar gene Proteins 0.000 description 1
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
241001291562 Martes pennanti Species 0.000 description 1
208000036626 Mental retardation Diseases 0.000 description 1
241000751119 Mila <angiosperm> Species 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
241001602688 Pama Species 0.000 description 1
101800001442 Peptide pr Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
108091034057 RNA (poly(A)) Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
101150060303 SOK2 gene Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000235342 Saccharomycetes Species 0.000 description 1
102100026737 Serine/threonine-protein kinase 25 Human genes 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
239000007997 Tricine buffer Substances 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
238000012197 amplification kit Methods 0.000 description 1
108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 1
230000003941 amyloidogenesis Effects 0.000 description 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
210000000576 arachnoid Anatomy 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
235000013405 beer Nutrition 0.000 description 1
230000006736 behavioral deficit Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000000476 body water Anatomy 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
206010008129 cerebral palsy Diseases 0.000 description 1
210000004289 cerebral ventricle Anatomy 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
101150116749 chuk gene Proteins 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
230000006999 cognitive decline Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
210000000877 corpus callosum Anatomy 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000010365 information processing Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
208000020658 intracerebral hemorrhage Diseases 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
238000005304 joining Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000010841 mRNA extraction Methods 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
230000002025 microglial effect Effects 0.000 description 1
230000004001 molecular interaction Effects 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
231100000189 neurotoxic Toxicity 0.000 description 1
230000002887 neurotoxic effect Effects 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000001936 parietal effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000003836 peripheral circulation Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
108010004093 retinal S antigen peptide M Proteins 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
239000006152 selective media Substances 0.000 description 1
230000001235 sensitizing effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
POECFFCNUXZPJT-UHFFFAOYSA-M sodium;carbonic acid;hydrogen carbonate Chemical compound [Na+].OC(O)=O.OC([O-])=O POECFFCNUXZPJT-UHFFFAOYSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
210000002330 subarachnoid space Anatomy 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000003868 tissue accumulation Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

UA2002086888A 2000-02-24 2001-02-26 A humanized antibody being associated with beta-amyloid peptide ((a?- polynucleic acid coding it, a pharmaceutical composition containing it, and use of said humanized antibody for making medicinal agent for prophylaxis and treatment of states associated with formation of beta-amyloid plaques UA75881C2 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US18460100P	2000-02-24	2000-02-24
US25449800P	2000-12-08	2000-12-08
US25446500P	2000-12-08	2000-12-08
PCT/US2001/006191 WO2001062801A2 (en)	2000-02-24	2001-02-26	Humanized antibodies that sequester amyloid beta peptide

Publications (1)

Publication Number	Publication Date
UA75881C2 true UA75881C2 (en)	2006-06-15

Family

ID=27391859

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002086888A UA75881C2 (en)	2000-02-24	2001-02-26	A humanized antibody being associated with beta-amyloid peptide ((a?- polynucleic acid coding it, a pharmaceutical composition containing it, and use of said humanized antibody for making medicinal agent for prophylaxis and treatment of states associated with formation of beta-amyloid plaques

Country Status (32)

Country	Link
US (4)	US7195761B2 (pt)
EP (4)	EP3070100B1 (pt)
JP (2)	JP4738696B2 (pt)
KR (1)	KR100767146B1 (pt)
CN (3)	CN104341500A (pt)
AT (1)	ATE279442T1 (pt)
AU (1)	AU4178601A (pt)
BR (1)	BRPI0108676B8 (pt)
CA (1)	CA2400559C (pt)
CY (1)	CY1118381T1 (pt)
CZ (2)	CZ2008595A3 (pt)
DE (2)	DE60106394T3 (pt)
DK (2)	DK1481992T3 (pt)
DZ (1)	DZ3295A1 (pt)
EA (1)	EA006606B1 (pt)
ES (2)	ES2184660T5 (pt)
HK (1)	HK1048640B (pt)
HR (2)	HRP20020693B1 (pt)
HU (2)	HUP0204074A3 (pt)
IL (3)	IL151378A0 (pt)
LT (1)	LT1481992T (pt)
MX (1)	MXPA02008145A (pt)
NO (2)	NO329840B1 (pt)
NZ (1)	NZ520800A (pt)
PL (2)	PL218883B1 (pt)
PT (2)	PT1257584E (pt)
SI (2)	SI1257584T2 (pt)
SK (2)	SK288723B6 (pt)
TR (1)	TR200202799T3 (pt)
UA (1)	UA75881C2 (pt)
WO (1)	WO2001062801A2 (pt)
ZA (1)	ZA200206712B (pt)

Families Citing this family (195)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US7964192B1 (en) *	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) *	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US7179892B2 (en) *	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en)	1997-12-02	2004-06-15	Neuralab Limited	Humanized and chimeric N-terminal amyloid beta-antibodies
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US20050059802A1 (en) *	1998-04-07	2005-03-17	Neuralab Ltd	Prevention and treatment of amyloidogenic disease
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
ATE405636T1 (de)	1999-06-16	2008-09-15	Boston Biomedical Res Inst	Immunologische kontrolle des beta-amyloid gehaltes in vivo
EP3070100B1 (en)	2000-02-24	2021-07-07	Washington University St. Louis	Humanized antibodies that sequester amyloid beta peptide
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) *	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
WO2002088307A2 (en) *	2001-04-30	2002-11-07	Eli Lilly And Company	Humanized antibodies
DE60230736D1 (de) *	2001-04-30	2009-02-26	Lilly Co Eli	HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9;
WO2003000714A2 (en) *	2001-06-22	2003-01-03	Panacea Pharmaceuticals, Inc.	Compositions and methods for preventing protein aggregation in neurodegenerative diseases
EP1420032B2 (en) †	2001-08-03	2015-12-16	Medical & Biological Laboratories Co., Ltd.	Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody
JP4511830B2 (ja) *	2001-08-17	2010-07-28	ワシントン・ユニバーシティ	アルツハイマー病のアッセイ方法
US20060073149A1 (en) *	2001-08-17	2006-04-06	Bales Kelly R	Rapid improvement of cognition in condition related to abeta
JP2005500389A (ja) *	2001-08-17	2005-01-06	イーライ・リリー・アンド・カンパニー	Ａβに関連する病態および疾患を治療するための、可溶性Ａβに高い親和性を有する抗体の使用
JP2005503789A (ja) *	2001-08-17	2005-02-10	イーライ・リリー・アンド・カンパニー	抗Ａβ抗体
EP1944040B1 (en)	2001-08-17	2012-08-01	Washington University	Assay method for Alzheimer's disease
US7179606B2 (en) *	2001-11-23	2007-02-20	Syn X Pharma, Inc.	IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
MY139983A (en) *	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
ES2318123T3 (es) *	2002-04-25	2009-05-01	Eli Lilly And Company	Procedimiento para tratar la ansiedad en sujetos de edad avanzada.
WO2004029629A1 (en) *	2002-09-27	2004-04-08	Janssen Pharmaceutica N.V.	N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
FR2846667B1 (fr) *	2002-11-06	2004-12-31	Pasteur Institut	Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
AU2003303198A1 (en)	2002-12-19	2004-07-14	New York University	Method for treating amyloid disease
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20060188512A1 (en) *	2003-02-01	2006-08-24	Ted Yednock	Active immunization to generate antibodies to solble a-beta
ATE468886T1 (de)	2003-02-10	2010-06-15	Applied Molecular Evolution	Abeta-bindende moleküle
US8663650B2 (en)	2003-02-21	2014-03-04	Ac Immune Sa	Methods and compositions comprising supramolecular constructs
US7732162B2 (en)	2003-05-05	2010-06-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
TWI374893B (en)	2003-05-30	2012-10-21	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
EP1638606B1 (en)	2003-06-27	2016-01-06	Amgen Fremont Inc.	Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
AT413336B (de)	2003-09-12	2006-02-15	Mattner Frank Dr	Apherese-vorrichtung
KR101139103B1 (ko) *	2003-09-12	2012-07-05	아피리스 아게	아페레시스 장치
US7848543B2 (en) *	2004-02-05	2010-12-07	Brainlab Ag	Method and system for prediction and management of material and information transport in an organism
PT1720909E (pt) *	2004-02-23	2011-12-23	Lilly Co Eli	Anticorpo anti-a¿ò
JPWO2005105998A1 (ja) *	2004-04-27	2008-07-31	財団法人化学及血清療法研究所	ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
EP1769002A1 (en) *	2004-07-02	2007-04-04	Northwestern University	Monolocal antibodies that target pathological assemblies of amyloid beta; (abeta)
US20060024667A1 (en)	2004-07-29	2006-02-02	Karen Manucharyan	Compositions and methods for Alzheimer's disease
CA2582194A1 (en) *	2004-10-05	2006-04-20	Neuralab Limited	Methods and compositions for improving recombinant protein production
US9907485B2 (en) *	2004-10-15	2018-03-06	Brainlab Ag	Targeted immunization and plaque destruction against Alzheimer's disease
US9901413B2 (en) *	2004-10-15	2018-02-27	Brainlab Ag	Targeted infusion of agents for treatment of ALS
US9924888B2 (en) *	2004-10-15	2018-03-27	Brainlab Ag	Targeted infusion of agents against parkinson's disease
PE20061329A1 (es) *	2004-12-15	2006-12-08	Neuralab Ltd	Anticuerpos ab humanizados para mejorar la cognicion
JP2008524247A (ja) *	2004-12-15	2008-07-10	エランファーマインターナショナルリミテッド	認知の改善における使用のためのアミロイドβ抗体
PE20061152A1 (es) *	2004-12-15	2006-10-13	Neuralab Ltd	Anticuerpos humanizados que reconocen el peptido beta amiloideo
WO2006069081A2 (en) *	2004-12-22	2006-06-29	Washington University In St. Louis	USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
EP1841455A1 (en) *	2005-01-24	2007-10-10	Amgen Inc.	Humanized anti-amyloid antibody
GT200600031A (es)	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
RU2415865C2 (ru)	2005-06-17	2011-04-10	Вайет	СПОСОБЫ ОЧИСТКИ БЕЛКОВ, СОДЕРЖАЩИХ ОБЛАСТЬ Fc
KR20180058863A (ko)	2005-11-30	2018-06-01	애브비 인코포레이티드	아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
RU2442793C2 (ru) *	2005-11-30	2012-02-20	Эбботт Лэборетриз	АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
EP2808032B1 (en) *	2005-12-12	2018-08-01	AC Immune S.A.	A beta 1-42 specific monoclonal antibodies with therapeutic properties
DOP2006000278A (es)	2005-12-12	2007-07-15	Hoffmann La Roche	Glicosilación en la región variable
AU2007233831B2 (en) *	2006-03-30	2013-02-14	Glaxo Group Limited	Antibodies against amyloid-beta peptide
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
CN101058608B (zh) *	2006-04-21	2011-02-23	杜如昱	人类抗Aβ1-32淀粉样蛋白抗体、其纯化方法及用途
RS56986B1 (sr) *	2006-07-14	2018-05-31	Ac Immune Sa	Humanizovana antitela na beta amiloid
CL2007002070A1 (es) *	2006-07-14	2008-02-08	Ac Immune S A Genentech Inc	Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
EP3988566A1 (en) *	2006-07-14	2022-04-27	AC Immune SA	Humanized antibody against amyloid beta
HUE033466T2 (en) *	2006-10-02	2017-12-28	Ac Immune Sa	Humanized antibody to beta-amyloid
AU2007308145A1 (en)	2006-10-12	2008-04-17	Wyeth	Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008084402A2 (en)	2007-01-11	2008-07-17	Philipps-Universitaet Marburg	Diagnosis and treatment of alzheimer's and other neurodementing diseases
RS53948B1 (en)	2007-01-18	2015-08-31	Eli Lilly And Company	PEGILATED AMYLOID BETA FAB
JP2010518064A (ja)	2007-02-12	2010-05-27	メルク・シャープ・エンド・ドーム・コーポレイション	Ａｄおよび関連状態の治療のためのピペラジン誘導体
WO2008104386A2 (en)	2007-02-27	2008-09-04	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
CN101668525A (zh)	2007-03-01	2010-03-10	前体生物药物股份公司	谷氨酰胺酰环化酶抑制剂的新用途
EP2865670B1 (en)	2007-04-18	2017-01-11	Probiodrug AG	Thiourea derivatives as glutaminyl cyclase inhibitors
JP2011526240A (ja) *	2007-04-18	2011-10-06	ヤンセンアルツハイマーイミュノセラピー	脳アミロイド血管症の予防および治療
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
CA2687330A1 (en)	2007-05-18	2008-11-27	The Johns Hopkins University	A treatment simulator for brain diseases and method of use thereof
US20090232801A1 (en) *	2007-05-30	2009-09-17	Abbot Laboratories	Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
JP2010528583A (ja) *	2007-06-11	2010-08-26	エーシーイミューンソシエテアノニム	アミロイドβに対するヒト化抗体
BRPI0812478A2 (pt) *	2007-06-12	2017-05-16	Ac Immune Sa	anticorpo quimérico ou um fragmento do mesmo, ou anticorpo humanizado ou um fragmento do mesmo, molécula de ácido nucleico, vetor de expressão, célula, composição, métodos de prevenir, tratar ou aliviar os efeitos d euma ou mais doenças, de diagnosticar uma doença ou condição associada com amilóide em um indivíduo, de determinar a extensão de carga de placa amiloidogênica em um tecido e/ou fluidos corporais de um indivíduo, de desagregar fibras beta-amilóides pré-formadas e de prevenir degradação de neurônios induzidas por abeta, kit de teste, região variável de cadeia, e, linhagem de célula
US8048420B2 (en) *	2007-06-12	2011-11-01	Ac Immune S.A.	Monoclonal antibody
US8613923B2 (en)	2007-06-12	2013-12-24	Ac Immune S.A.	Monoclonal antibody
SI2182983T1 (sl)	2007-07-27	2014-09-30	Janssen Alzheimer Immunotherapy	Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
EP2197914A1 (en) *	2007-09-13	2010-06-23	Delenex Therapeutics AG	HUMANIZED ANTIBODIES AGAINST THE ß-AMYLOYD PEPTIDE
UA101167C2 (ru) *	2007-10-05	2013-03-11	Дженентек, Инк.	Фармацевтическая композиция, предназначенная для лечения глазной болезни
AU2008311367B2 (en)	2007-10-05	2014-11-13	Ac Immune S.A.	Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
MY158903A (en) *	2007-11-16	2016-11-30	Univ Rockefeller	Antibodies specific for the protofibril form of beta-amyloid protein
CA2709354C (en)	2007-12-21	2014-06-17	Amgen Inc.	Anti-amyloid antibodies and uses thereof
EP2106802A1 (en)	2008-04-02	2009-10-07	SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.	Modified peptides as synthetic vaccines in amyloid-associated disease
EP2149380A1 (en) *	2008-07-29	2010-02-03	Medivet Pharma, S.L.	Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
WO2010024927A2 (en)	2008-08-28	2010-03-04	The Research Foundation Of State University Of New York	Treatment of amyloidoses using myelin basic protein and fragments thereof
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
US8614297B2 (en) *	2008-12-22	2013-12-24	Hoffmann-La Roche Inc.	Anti-idiotype antibody against an antibody against the amyloid β peptide
EP2475428B1 (en)	2009-09-11	2015-07-01	Probiodrug AG	Heterocylcic derivatives as inhibitors of glutaminyl cyclase
KR101531949B1 (ko)	2009-12-11	2015-06-26	아라클론 바이오테크, 에스.엘.	아밀로이드 베타 펩티드의 개선된 검출 방법 및 시약
EP2542581A4 (en)	2010-03-01	2014-01-22	David Gladstone Inst	SPECIFIC APOLIPOPROTEIN ANTIBODY AND METHODS OF USING SAME
US9181233B2 (en)	2010-03-03	2015-11-10	Probiodrug Ag	Inhibitors of glutaminyl cyclase
AU2011226074B2 (en)	2010-03-10	2015-01-22	Vivoryon Therapeutics N.V.	Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
ES2684475T3 (es)	2010-04-15	2018-10-03	Abbvie Inc.	Proteínas que se unen a beta amiloide
WO2011131748A2 (en)	2010-04-21	2011-10-27	Probiodrug Ag	Novel inhibitors
WO2011149461A1 (en)	2010-05-27	2011-12-01	Medtronic, Inc.	Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
WO2012016173A2 (en)	2010-07-30	2012-02-02	Ac Immune S.A.	Safe and functional humanized antibodies
WO2012019168A2 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
US9062101B2 (en)	2010-08-14	2015-06-23	AbbVie Deutschland GmbH & Co. KG	Amyloid-beta binding proteins
DE19177059T1 (de)	2010-10-01	2021-10-07	Modernatx, Inc.	N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
DK2686313T3 (en)	2011-03-16	2016-05-02	Probiodrug Ag	Benzimidazole derivatives as inhibitors of glutaminyl cyclase
ES2602794T3 (es)	2011-03-31	2017-02-22	Pfizer Inc	Piridinonas bicíclicas novedosas
DE12722942T1 (de)	2011-03-31	2021-09-30	Modernatx, Inc.	Freisetzung und formulierung von manipulierten nukleinsäuren
EP2511296A1 (en)	2011-04-12	2012-10-17	Araclón Biotech, S. L.	Antibody, kit and method for determination of amyloid peptides
WO2012172449A1 (en)	2011-06-13	2012-12-20	Pfizer Inc.	Lactams as beta secretase inhibitors
JP6043355B2 (ja)	2011-08-31	2016-12-14	ファイザー・インク	ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
JP2012050437A (ja) *	2011-09-12	2012-03-15	Janssen Alzheimer Immunotherapy	ベータアミロイドペプチドを認識するヒト化抗体
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja)	2011-10-03	2017-04-12	モデルナティエックスインコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ．	修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
MX2014007233A (es)	2011-12-16	2015-02-04	Moderna Therapeutics Inc	Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
JP2015502165A (ja)	2011-12-22	2015-01-22	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	発現ベクター構成、新規の産生細胞生成法、およびポリペプチドの組換え産生のためのそれらの使用
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en)	2012-04-02	2019-12-10	Modernatx, Inc.	Modified polynucleotides
EP2834259A4 (en)	2012-04-02	2016-08-24	Moderna Therapeutics Inc	MODIFIED POLYNUCLEOTIDES
WO2013164730A1 (en)	2012-05-04	2013-11-07	Pfizer Inc.	Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2.
KR20150027267A (ko)	2012-06-29	2015-03-11	화이자 인코포레이티드	LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘
JP2015526409A (ja) *	2012-07-03	2015-09-10	ヤンセン・サイエンシズ・アイルランド・ユーシー	Ｃ−末端及び中心エピトープａ−ベータ抗体
CA2882389A1 (en)	2012-09-20	2014-03-27	Pfizer Inc.	Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk)	2012-09-21	2016-01-25	Пфайзер Інк.	Біциклічні піридинони
CA2892529C (en)	2012-11-26	2023-04-25	Moderna Therapeutics, Inc.	Terminally modified rna
WO2014091352A1 (en)	2012-12-11	2014-06-19	Pfizer Inc.	Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
CA2893333C (en)	2012-12-19	2017-10-24	Pfizer Inc.	Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
JP2016507551A (ja)	2013-02-13	2016-03-10	ファイザー・インク	ヘテロアリール置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
US9233981B1 (en)	2013-02-15	2016-01-12	Pfizer Inc.	Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
MD20150071A2 (ro)	2013-02-19	2016-02-29	Pfizer Inc.	Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
MA38632B1 (fr)	2013-05-20	2019-10-31	Genentech Inc	Anticorps anti-récepteur de transferrine et procédés d'utilisation
NZ756750A (en)	2013-09-13	2022-05-27	Genentech Inc	Methods and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl)	2013-09-13	2022-06-27	F.Hoffmann-La Roche Ag	Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
WO2015048744A2 (en)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en)	2013-10-03	2015-04-09	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
EP3052495B1 (en)	2013-10-04	2019-06-26	Pfizer Inc	Novel bicyclic pyridinones as gamma-secretase modulators
WO2015092592A1 (en)	2013-12-17	2015-06-25	Pfizer Inc.	Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CA2944308A1 (en)	2014-04-01	2015-10-08	Pfizer Inc.	Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
MA39866A (fr)	2014-04-10	2017-02-15	Pfizer	Amides 2-amino-6-méthyl-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yle
WO2015165961A1 (en)	2014-04-29	2015-11-05	Affiris Ag	Treatment and prevention of alzheimer's disease (ad)
JP6713982B2 (ja)	2014-07-24	2020-06-24	ファイザー・インク	ピラゾロピリミジン化合物
JP6506833B2 (ja)	2014-08-06	2019-04-24	ファイザー・インク	イミダゾピリダジン化合物
SI3221349T1 (sl)	2014-11-19	2021-02-26	Axon Neuroscience Se	Humanizirano tau protitelo pri alzheimerjevi bolezni
CN107250158B (zh)	2014-11-19	2022-03-25	基因泰克公司	抗转铁蛋白受体/抗bace1多特异性抗体和使用方法
EP3221362B1 (en)	2014-11-19	2019-07-24	F.Hoffmann-La Roche Ag	Anti-transferrin receptor antibodies and methods of use
EA033423B1 (ru)	2015-02-03	2019-10-31	Pfizer	Циклопропанбензофуранилпиридопиразиндионы
DK3766885T3 (da)	2015-06-17	2022-08-01	Pfizer	Tricykliske forbindelser og deres anvendelse som phoshodiesteraseinhibitorer
CA2991856A1 (en)	2015-07-21	2017-01-26	Bioarctic Neuroscience Ab	Method for treatment of traumatic brain injury targeting aggregated peptides
MX2018003215A (es)	2015-09-14	2018-06-08	Pfizer	Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.
EP3353174A1 (en)	2015-09-24	2018-08-01	Pfizer Inc	N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors
JP2018531923A (ja)	2015-09-24	2018-11-01	ファイザー・インク	Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
JP2018531924A (ja)	2015-09-24	2018-11-01	ファイザー・インク	テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
US11135313B2 (en)	2015-10-28	2021-10-05	The Trustees Of The University Of Pennsylvania	Intrathecal administration of adeno-associated-viral vectors for gene therapy
CN108350053A (zh)	2015-11-09	2018-07-31	英属哥伦比亚大学	淀粉样蛋白β表位及其抗体
KR20180088828A (ko)	2015-11-09	2018-08-07	더 유니버시티 오브 브리티쉬 콜롬비아	아밀로이드 베타에서의 n-말단 에피토프 및 이에 형태적으로-선택적인 항체
JP7448174B2 (ja) *	2015-11-09	2024-03-12	ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア	アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
AU2017223132B2 (en)	2016-02-23	2019-12-05	Pfizer Inc.	6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
CN109641898B (zh)	2016-07-01	2022-04-08	辉瑞公司	用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物
TWI798751B (zh)	2016-07-01	2023-04-11	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途
JP6949102B2 (ja) *	2016-08-09	2021-10-13	イーライリリーアンドカンパニー	併用療法
CN110036033B (zh)	2016-09-27	2023-12-08	森罗治疗公司	嵌合吞噬受体分子
AU2017350947B2 (en)	2016-10-28	2024-02-15	Washington University	Anti-ApoE antibodies
US20180125920A1 (en)	2016-11-09	2018-05-10	The University Of British Columbia	Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
WO2018163066A1 (en)	2017-03-10	2018-09-13	Pfizer Inc.	Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
ES2910083T3 (es)	2017-03-10	2022-05-11	Pfizer	Derivados de imidazo[4,5-c]quinolina cíclicos sustituidos
JOP20190247A1 (ar) *	2017-04-20	2019-10-20	Lilly Co Eli	أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
CN110997693A (zh)	2017-06-07	2020-04-10	阿德克斯公司	τ聚集抑制剂
CN110944998B (zh)	2017-06-22	2022-08-16	辉瑞大药厂	二氢-吡咯并-吡啶衍生物
CA3067597C (en)	2017-06-29	2023-03-21	The Trustees Of Columbia University In The City Of New York	Chimeric antibodies for treatment of amyloid deposition diseases
JP7330164B2 (ja)	2017-07-18	2023-08-21	ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア	アミロイドベータに対する抗体
US11382974B2 (en)	2017-08-01	2022-07-12	The Trustees Of Columbia University In The City Of New York	Methods and compositions for treatment of amyloid deposition diseases
WO2019036725A2 (en)	2017-08-18	2019-02-21	Adrx, Inc.	PEPTIDE INHIBITORS OF TAU AGGREGATION
KR20200100598A (ko)	2017-09-26	2020-08-26	세로 테라퓨틱스, 인코포레이티드	키메라 포식작용 수용체 분자 및 사용 방법
DK3461819T3 (da)	2017-09-29	2020-08-10	Probiodrug Ag	Inhibitorer af glutaminylcyklase
WO2019074840A1 (en) *	2017-10-09	2019-04-18	Keith Black	COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOID RELATED DISEASES
HUE061533T2 (hu)	2018-03-23	2023-07-28	Pfizer	Piperazin azaspiro származékok
WO2019191332A1 (en)	2018-03-28	2019-10-03	Cero Therapeutics, Inc.	Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
US20210309726A1 (en) *	2018-05-21	2021-10-07	New York University	Treatment of melanoma brain metastasis by inhibition of amyloid precursor protein cleavage
CN113226283A (zh)	2018-10-04	2021-08-06	罗切斯特大学	通过操纵血浆重量摩尔渗透压浓度改善淋巴递送
WO2020132230A2 (en)	2018-12-20	2020-06-25	Genentech, Inc.	Modified antibody fcs and methods of use
FR3091999A1 (fr) *	2019-01-25	2020-07-31	Mexbrain	Dispositif d’extraction conjointe d’un cation métallique et d’une molécule cible
JP2022552323A (ja)	2019-10-15	2022-12-15	イーライリリーアンドカンパニー	組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株
CN116348487A (zh)	2020-07-23	2023-06-27	欧萨尔普罗席纳有限公司	抗淀粉样β抗体
IL304072A (en)	2021-01-11	2023-08-01	Lilly Co Eli	ANTI-N3PGLU AMYLOID BETA ANTIBODIES AND USES THEREOF
TW202300518A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗類澱粉β抗體及其用途
WO2022251048A1 (en)	2021-05-24	2022-12-01	Eli Lilly And Company	Anti-amyloid beta antibodies and uses thereof
WO2023150483A1 (en)	2022-02-03	2023-08-10	Eli Lilly And Company	Regional tau imaging for diagnosing and treating alzheimer's disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5278049A (en) *	1986-06-03	1994-01-11	Incyte Pharmaceuticals, Inc.	Recombinant molecule encoding human protease nexin
FR2608669A1 (fr)	1986-12-19	1988-06-24	Boussois Sa	Vitrage pret a sa pose et son procede de fabrication et de fixation
US4933156A (en)	1987-04-08	1990-06-12	Salutar, Inc.	Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
US5004697A (en)	1987-08-17	1991-04-02	Univ. Of Ca	Cationized antibodies for delivery through the blood-brain barrier
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5753624A (en) *	1990-04-27	1998-05-19	Milkhaus Laboratory, Inc.	Materials and methods for treatment of plaquing disease
US5837822A (en) *	1992-01-27	1998-11-17	Icos Corporation	Humanized antibodies specific for ICAM related protein
US5837672A (en)	1992-07-10	1998-11-17	Athena Neurosciences, Inc.	Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en)	1992-07-10	1998-06-16	Athena Neurosciences	Methods of screening for compounds which inhibit soluble β-amyloid peptide production
WO1994010569A1 (en) *	1992-10-26	1994-05-11	Schenk Dale B	METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE β-AMYLOID PEPTIDE
CA2115900A1 (en)	1993-02-22	1994-08-23	Gerald W. Becker	Pharmaceutical screens and antibodies
WO1995009236A1 (en) *	1993-09-28	1995-04-06	The General Hospital Corporation	USING ANTISENSE OLIGONUCLEOTIDES TO MODULATE NERVE GROWTH AND TO REVERSE β/A4 AMYLOID-INDUCED MORPHOLOGY
JPH09511492A (ja) *	1994-02-03	1997-11-18	ザピコワーインスティテュートフォアメディカルリサーチ	アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法
US5688651A (en) *	1994-12-16	1997-11-18	Ramot University Authority For Applied Research And Development Ltd.	Prevention of protein aggregation
US5786180A (en)	1995-02-14	1998-07-28	Bayer Corporation	Monoclonal antibody 369.2B specific for β A4 peptide
US6037454A (en) *	1996-11-27	2000-03-14	Genentech, Inc.	Humanized anti-CD11a antibodies
US6218506B1 (en) *	1997-02-05	2001-04-17	Northwestern University	Amyloid β protein (globular assembly and uses thereof)
US20020086847A1 (en) *	1997-04-09	2002-07-04	Mindset Biopharmaceuticals (Usa)	Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
EP2305709A1 (en)	1997-04-09	2011-04-06	Intellect Neurosciences, Inc.	Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof
US6787319B2 (en) *	1997-04-16	2004-09-07	American Home Products Corp.	β-amyloid peptide-binding proteins and polynucleotides encoding the same
IT1293511B1 (it)	1997-07-30	1999-03-01	Gentili Ist Spa	Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
JP2001512689A (ja) *	1997-08-11	2001-08-28	カイロンコーポレイション	Ｔ細胞を遺伝子改変するための方法
TWI239847B (en) *	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
NZ507727A (en)	1998-05-21	2003-11-28	Univ Tennessee Res Foundation	Methods for amyloid removal using anti-amloid antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
ATE405636T1 (de)	1999-06-16	2008-09-15	Boston Biomedical Res Inst	Immunologische kontrolle des beta-amyloid gehaltes in vivo
EP1571158B1 (en)	1999-08-04	2009-10-14	University Of Southern California	Globular assembly of amyloid beta protein and uses thereof
CA2349434A1 (en)	1999-09-03	2001-03-15	Ramot University Authority For Applied Research & Industrial Development Ltd.	Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
US6294171B2 (en)	1999-09-14	2001-09-25	Milkhaus Laboratory, Inc.	Methods for treating disease states comprising administration of low levels of antibodies
EP3070100B1 (en)	2000-02-24	2021-07-07	Washington University St. Louis	Humanized antibodies that sequester amyloid beta peptide
US20020009445A1 (en) *	2000-07-12	2002-01-24	Yansheng Du	Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
ATE441663T1 (de)	2000-09-06	2009-09-15	Aventis Pharma Sa	Verfahren und zusammensetzungen für amyloidosis- verbundene krankheiten
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
JP4511830B2 (ja)	2001-08-17	2010-07-28	ワシントン・ユニバーシティ	アルツハイマー病のアッセイ方法

2001
- 2001-02-26 EP EP16161726.1A patent/EP3070100B1/en not_active Expired - Lifetime
- 2001-02-26 PL PL386125A patent/PL218883B1/pl unknown
- 2001-02-26 CZ CZ2008-595A patent/CZ2008595A3/cs not_active IP Right Cessation
- 2001-02-26 ES ES01913081T patent/ES2184660T5/es not_active Expired - Lifetime
- 2001-02-26 SK SK69-2008A patent/SK288723B6/sk not_active IP Right Cessation
- 2001-02-26 DK DK04011466.2T patent/DK1481992T3/en active
- 2001-02-26 BR BRPI0108676A patent/BRPI0108676B8/pt not_active IP Right Cessation
- 2001-02-26 CN CN201410322976.0A patent/CN104341500A/zh active Pending
- 2001-02-26 EA EA200200897A patent/EA006606B1/ru not_active IP Right Cessation
- 2001-02-26 IL IL15137801A patent/IL151378A0/xx unknown
- 2001-02-26 PL PL356798A patent/PL210157B1/pl unknown
- 2001-02-26 TR TR2002/02799T patent/TR200202799T3/xx unknown
- 2001-02-26 HU HU0204074A patent/HUP0204074A3/hu unknown
- 2001-02-26 CN CN200810214672.7A patent/CN101670105B/zh not_active Expired - Lifetime
- 2001-02-26 LT LTEP04011466.2T patent/LT1481992T/lt unknown
- 2001-02-26 DE DE60106394T patent/DE60106394T3/de not_active Expired - Lifetime
- 2001-02-26 DK DK01913081.4T patent/DK1257584T4/da active
- 2001-02-26 AU AU4178601A patent/AU4178601A/xx active Pending
- 2001-02-26 WO PCT/US2001/006191 patent/WO2001062801A2/en active Application Filing
- 2001-02-26 KR KR1020027011027A patent/KR100767146B1/ko active IP Right Grant
- 2001-02-26 SI SI200130240T patent/SI1257584T2/sl unknown
- 2001-02-26 NZ NZ520800A patent/NZ520800A/en not_active IP Right Cessation
- 2001-02-26 ES ES04011466.2T patent/ES2611427T3/es not_active Expired - Lifetime
- 2001-02-26 SK SK12212002A patent/SK288711B6/sk not_active IP Right Cessation
- 2001-02-26 CA CA2400559A patent/CA2400559C/en not_active Expired - Lifetime
- 2001-02-26 EP EP16196667.6A patent/EP3150633A1/en not_active Withdrawn
- 2001-02-26 EP EP04011466.2A patent/EP1481992B1/en not_active Expired - Lifetime
- 2001-02-26 JP JP2001562582A patent/JP4738696B2/ja not_active Expired - Lifetime
- 2001-02-26 AT AT01913081T patent/ATE279442T1/de active
- 2001-02-26 PT PT01913081T patent/PT1257584E/pt unknown
- 2001-02-26 SI SI200131058A patent/SI1481992T1/sl unknown
- 2001-02-26 MX MXPA02008145A patent/MXPA02008145A/es active IP Right Grant
- 2001-02-26 PT PT40114662T patent/PT1481992T/pt unknown
- 2001-02-26 DE DE1257584T patent/DE1257584T1/de active Pending
- 2001-02-26 EP EP01913081A patent/EP1257584B2/en not_active Expired - Lifetime
- 2001-02-26 CZ CZ2002-2851A patent/CZ304211B6/cs not_active IP Right Cessation
- 2001-02-26 CN CN018084303A patent/CN1426423B/zh not_active Expired - Lifetime
- 2001-02-26 DZ DZ013295A patent/DZ3295A1/fr active
- 2001-02-26 UA UA2002086888A patent/UA75881C2/uk unknown
2002
- 2002-08-20 NO NO20023957A patent/NO329840B1/no not_active IP Right Cessation
- 2002-08-21 ZA ZA200206712A patent/ZA200206712B/en unknown
- 2002-08-21 IL IL151378A patent/IL151378A/en active IP Right Grant
- 2002-08-21 US US10/226,435 patent/US7195761B2/en not_active Expired - Lifetime
- 2002-08-22 HR HR20020693A patent/HRP20020693B1/xx not_active IP Right Cessation
2003
- 2003-01-02 HK HK03100011.2A patent/HK1048640B/zh active IP Right Maintenance
2005
- 2005-09-12 US US11/224,623 patent/US20060039906A1/en not_active Abandoned
2008
- 2008-02-08 US US12/028,641 patent/US7892545B2/en not_active Expired - Fee Related
- 2008-08-21 IL IL193631A patent/IL193631A/en active IP Right Grant
- 2008-09-03 HR HRP20080430AA patent/HRP20080430B1/hr not_active IP Right Cessation
- 2008-09-04 NO NO20083805A patent/NO337363B1/no not_active IP Right Cessation
- 2008-09-19 JP JP2008240971A patent/JP4914412B2/ja not_active Expired - Lifetime
2010
- 2010-12-22 US US12/976,282 patent/US8591894B2/en not_active Expired - Lifetime
2011
- 2011-02-26 HU HU0800571A patent/HU230768B1/hu unknown
2016
- 2016-12-15 CY CY20161101301T patent/CY1118381T1/el unknown

Also Published As

Publication number	Publication date
PL218883B1 (pl)	2015-02-27
ATE279442T1 (de)	2004-10-15
HUP0800571A2 (en)	2003-03-28
EP1257584A2 (en)	2002-11-20
NO337363B1 (no)	2016-03-29
IL151378A0 (en)	2003-04-10
DE60106394D1 (de)	2004-11-18
ES2611427T3 (es)	2017-05-08
BR0108676A (pt)	2003-01-07
PL356798A1 (en)	2004-07-12
PT1481992T (pt)	2017-01-02
HK1048640A1 (en)	2003-04-11
EP3070100B1 (en)	2021-07-07
SI1257584T1 (en)	2005-04-30
SI1257584T2 (sl)	2013-07-31
EA006606B1 (ru)	2006-02-24
US20090238821A1 (en)	2009-09-24
CZ20022851A3 (cs)	2003-09-17
CA2400559A1 (en)	2001-08-30
HU230768B1 (hu)	2018-03-28
EP3070100A1 (en)	2016-09-21
HRP20020693B1 (en)	2012-01-31
SK288723B6 (sk)	2020-01-07
EP1257584B9 (en)	2004-12-01
US20060039906A1 (en)	2006-02-23
HRP20080430A9 (en)	2009-02-28
ZA200206712B (en)	2003-11-21
EA200200897A1 (ru)	2003-02-27
SI1481992T1 (sl)	2017-01-31
NO20023957L (no)	2002-10-22
CZ306683B6 (cs)	2017-05-03
DZ3295A1 (fr)	2001-08-30
KR100767146B1 (ko)	2007-10-15
LT1481992T (lt)	2017-02-10
DE1257584T1 (de)	2003-05-28
NO329840B1 (no)	2011-01-10
TR200202799T3 (tr)	2003-03-21
EP1257584B1 (en)	2004-10-13
WO2001062801A3 (en)	2002-01-31
CZ304211B6 (cs)	2014-01-08
DE60106394T3 (de)	2013-07-25
HUP0204074A2 (hu)	2003-03-28
CY1118381T1 (el)	2017-06-28
HRP20080430A2 (en)	2008-11-30
SK288711B6 (sk)	2019-11-05
CN101670105A (zh)	2010-03-17
JP2009046497A (ja)	2009-03-05
NO20023957D0 (no)	2002-08-20
JP4914412B2 (ja)	2012-04-11
ES2184660T3 (es)	2005-05-01
JP2003523764A (ja)	2003-08-12
EP3150633A1 (en)	2017-04-05
ES2184660T5 (es)	2013-05-09
EP1481992A3 (en)	2004-12-08
NZ520800A (en)	2004-04-30
US8591894B2 (en)	2013-11-26
US7892545B2 (en)	2011-02-22
MXPA02008145A (es)	2004-04-05
NO20083805L (no)	2002-10-22
EP1481992B1 (en)	2016-11-02
HUP0204074A3 (en)	2004-07-28
DK1481992T3 (en)	2017-01-30
EP1481992A2 (en)	2004-12-01
SK12212002A3 (sk)	2003-10-07
CN1426423B (zh)	2010-05-12
PT1257584E (pt)	2005-01-31
HRP20080430B1 (hr)	2016-12-16
JP4738696B2 (ja)	2011-08-03
CN1426423A (zh)	2003-06-25
CN104341500A (zh)	2015-02-11
EP1257584B2 (en)	2013-03-06
BRPI0108676B1 (pt)	2015-09-15
HRP20020693A2 (en)	2004-12-31
US20110158986A1 (en)	2011-06-30
KR20020089359A (ko)	2002-11-29
HK1048640B (zh)	2005-04-01
IL193631A (en)	2010-11-30
IL151378A (en)	2010-04-29
DE60106394T2 (de)	2006-03-09
US20040043418A1 (en)	2004-03-04
CN101670105B (zh)	2014-08-06
US7195761B2 (en)	2007-03-27
AU4178601A (en)	2001-09-03
IL193631A0 (en)	2009-02-11
DK1257584T3 (da)	2005-01-17
DK1257584T4 (da)	2013-03-25
PL210157B1 (pl)	2011-12-30
CA2400559C (en)	2012-05-01
WO2001062801A2 (en)	2001-08-30
BRPI0108676B8 (pt)	2021-05-25
CZ2008595A3 (cs)	2017-05-03
ES2184660T1 (es)	2003-04-16

Publication	Publication Date	Title
UA75881C2 (en)	2006-06-15	A humanized antibody being associated with beta-amyloid peptide ((a?- polynucleic acid coding it, a pharmaceutical composition containing it, and use of said humanized antibody for making medicinal agent for prophylaxis and treatment of states associated with formation of beta-amyloid plaques
JP6251234B2 (ja)	2017-12-20	Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法
EP1910829B1 (en)	2016-03-02	Prevention and treatment of synucleinopathic and amyloidogenic disease
EA016193B1 (ru)	2012-03-30	Антитела, направленные против бета-амилоидного пептида, и способы их использования
US20190161535A1 (en)	2019-05-30	Compositions and methods for treating spinal muscular atrophy
JPWO2006013904A1 (ja)	2008-05-01	メルトリンアンタゴニストを含有する医薬組成物
US20170128544A1 (en)	2017-05-11	Uses of Humanized Cobra Venom Factor for Reducing or Preventing Immunogenicity